Skip to main navigation
Skip to main content
Schrödinger

    Client Secondary Menu

  • Download
  • Contact
  • Support

    About

  • About
      • Team
      • Our Story
      • Culture
      • Diversity & Inclusion
      • Platform

      • Platform
          • Overview
          • Drug Discovery
          • Materials Science
          • All Products A-Z
          • Publications
          • Pipeline

          • Pipeline
          • User Events

          • User Events
          • Careers

          • Careers
          • Investor Relations (Sub Menu)

          • Investor Relations
              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

                Investor Relations (Sub Menu)

              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

              Press Release

              News & Events ( third-level-submenu)

              • Press Releases
              • Event Calendar

              Schrödinger to Host Second Quarter 2020 Financial Results Conference Call and Webcast

              August 3, 2020
              PDF Version

              NEW YORK--(BUSINESS WIRE)--Aug. 3, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that it will host a conference call and webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss second quarter 2020 financial results and provide a general business update.

              Interested participants and investors may access the conference call by dialing (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 9992538. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on the Company's website following the event.

              About Schrödinger

              Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. In addition to this global business, Schrödinger is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies. In addition, Schrödinger is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has over 400 employees in its New York City headquarters and around the world. Visit www.schrodinger.com for more information.

              View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005108/en/

              Media:
              Stephanie Simon
              Ten Bridge Communications
              stephanie@tenbridgecommunications.com
              617-581-9333

              Investors:
              Christina Tartaglia
              Stern IR, Inc.
              christina.tartaglia@sternir.com
              212-362-1200

              Source: Schrödinger

              Investor Tools

              • Email Alerts
              • Email Alerts
              • Investor Contact
              • Investor Contact
              • Print Page
              • Print Page
              • Email Page
              • Email Page

              Social Menu

              Twitter Youtube} Google Linkedin

              Copyright © 2021 Schrödinger, Inc.

                Legal Menu

              • Citations
              • Privacy Policies
              • Terms of Use
              • FCOI Policy
              • EULA
              Back To Top